First-Row Transition 7-Oxo-5-phenyl-1,2,4-triazolo[1,5-a]pyrimidine Metal Complexes: Antiparasitic Activity and Release Studies
Metadata
Show full item recordAuthor
Martín Montes, Álvaro Miguel; Jiménez-Falcao, Sandra; Gómez-Ruiz, Santiago; Marín Sánchez, Clotilde; Méndez Arriaga, José ManuelEditorial
MDPI
Materia
Metal complex Coordination chemistry Leishmaniasis Antiparasitic activity Drug release Nanoparticles
Date
2023-09-28Referencia bibliográfica
Martín-Montes, Á.; Jimenez-Falcao, S.; Gómez-Ruiz, S.; Marín, C.; Mendez-Arriaga, J.M. First-Row Transition 7-Oxo-5-phenyl- 1,2,4-triazolo[1,5-a]pyrimidine Metal Complexes: Antiparasitic Activity and Release Studies. Pharmaceuticals 2023, 16, 1380. [https://doi.org/10.3390/ph16101380]
Sponsorship
MCIN/AEI/10.13039/501100011033/ RTI2018-094322-B-I00, RED2022-134091-T; ERDF A way of making Europe; European Union; Junta de AndalucíaAbstract
Leishmaniasis and Chagas disease are still considered neglected illnesses due to the lack of investment in research, despite the fact that almost one million new cases are reported every year. Four 7-oxo-5-phenyl-1,2,4-triazolo[1,5-a]pyrimidine (HftpO) first-row transition complexes (Cu, Co, Ni, Zn) have been studied for the first time in vitro against five different species of Leishmania spp. (L. infantum, L. braziliensis, L. donovani, L. peruviana and L. mexicana) as well as Trypanosoma cruzi, showing higher efficacy than the reference commercial drugs. UV and luminescence properties were also evaluated. As a proof of concept, anchoring of a model high-effective-metal complex as an antiparasitic agent on silica nanoparticles was carried out for the first time, and drug-release behaviour was evaluated, assessing this new approach for drug vehiculation.